* Humacyte Inc HUMA.OQ HUMA.O is expected to show no
change in
quarterly revenue when it reports results on May 10 for the
period ending January 1 0001
*
* LSEG's mean analyst estimate for Humacyte Inc is for a
loss
of 22 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Humacyte
Inc is
$6.50, above its last closing price of $4.61.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.25 -0.24 -0.24 Met 2
Sep. 30 0001 -0.25 -0.25 -0.25 Met 1.3
Jun. 30 2023 -0.22 -0.22 -0.22 Met -0.1
Mar. 31 2023 -0.21 -0.21 -0.36 Missed -71.8
Dec. -0.23 -0.04 Beat 83
31 2022
Sep. 30 2022 -0.22 -0.21 -0.25 Missed -16.3
Jun. 30 2022 -0.22 -0.22 0.35 Beat 260.3
Mar. 31 2022 -0.21 -0.21 -0.19 Beat 8.1
This summary was machine generated May 8 at 13:59 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)